EGFR and non-small cell lung carcinoma: Mobocertinib received FDA approval for NSCLC patients harboring EGFR ex20ins who had progressed following platinum-based chemotherapy, based on an ORR of 28% and a mPFS of 7.3 months (Zhou et al., 2021).